Efficacy of Oocyte Activation With Two Types of Ca2+ Ionophore.
- Registration Number
- NCT06106412
- Lead Sponsor
- Instituto Valenciano de Infertilidad, IVI VALENCIA
- Brief Summary
This study is a prospective ranzomized analysis including 372 human oocytes from 44 women. Half of the oocytes from the same patient will be randomly allocated to induce oocyte activation using two protocols: in protocol nº 1 we will use ionomycin (prepared solution), protocol nª2 A23187 (GM508 CultActive Gynemed) will be applied. Non treated oocytes will serve as control. Oocyte fertilization rates, embryo development and embryo quality will be analyzed. Obstetrics variables of offspring will be also followed and compared.
- Detailed Description
Background: Oocyte non-activation (OAD) is the main cause of fertilization failure in intracytoplasmic sperm injection (ICSI) cycles. Oocyte activation involves a series of consecutive events that take place in the oocyte during fertilization, triggered by the action of sperm-specific phospholipase C zeta (PLCz) that causes an increase in the amount of free Ca2+. This increase, as well as its transient elevations in space and time, is species-specific. Defects in this pattern of Ca2+ release and oscillation are attributed to most cases of OAD. Several strategies have been described and applied to achieve artificial oocyte activation (AOA), which use mechanical, electrical, or chemical stimuli, among which the use of calcium ionophores such as ionomycin and A23187 (calcimycin) predominates. Documented fertilization and pregnancy rates appear to be improved in patients with previous low fertilization rates or total fertilization failures after using ICSI-AOA compared to conventional ICSI. However, the lack of well-designed studies, the heterogeneity of the population undergoing AOA, and the scarcity of results comparing different AOA protocols make it difficult to assess the clinical efficacy and safety of the technique.
Study question: In patients with prior fertilization failure or low fertilization rates (30% or less), does AOA improve reproductive outcomes compared to conventional ICSI in patients with prior fertilization failure? and if it does, which protocol is more efficient?
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 44
- Own oocyte patients who have had previous fertilization failure in previous cycles.
- Own oocyte patients with fertilization rate in previous cycles less than or equal to 30% of the microinjected oocytes.
- Oocyte Recipient Patients
- Sperm bank sperm recipient patients
- Patients who after oocyte decumulation have less than 2 mature oocytes.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description GROUP 1 IONOMYCIN SIGMA Ionomycin SIGMA The oocytes obtained from the patients allocated to this group will be subdivided again in two groups Group 1a: Oocytes treated with SIGMA ionomycin (treatment). Group 1b: Oocytes that will not be treated with any activator (Control). GROUP 2 A23187 A23187 The oocytes obtained from the patients allocated to this group will be subdivided again in two groups Group 2a: Oocytes treated with A23187 (treatment). Group 2b: Oocytes that will not be treated with any activator (Control).
- Primary Outcome Measures
Name Time Method Improvement in the percetage of usable blastocyst per injeected oocyte 1 YEAR To evaluate which AOA protocol with the use of two calcium (Ca2+) ionophores, ionomycin and A23187 (calcimycin), is better (improvement from 15% to 25%)
- Secondary Outcome Measures
Name Time Method Sequencing unfertilized oocytes and arrested embryos using RNAseq 1 year To quantify sequenced oocytes and arrested embryos after using RNAseq
Quantification of PLCZ in sperm cells by flow 1 year To quantify PLCZ in sperm
Trial Locations
- Locations (1)
Ivirma Valencia
🇪🇸Valencia, Spain